What's Happening?
The 10th Tumor Models Summit in San Francisco is bringing together leaders in the pharmaceutical and biotech industries to discuss advancements in tumor modeling. This event comes at a time when the FDA is phasing out animal testing requirements, and the NIH
is redirecting funding away from animal-only studies. The summit focuses on innovative modalities such as ADCs, bispecifics, and T-cell engagers, which require more predictive models. Technologies like CRISPR and AI are accelerating the development of patient-derived models, offering new opportunities for optimizing model selection strategies. Industry leaders and vendors are collaborating to navigate these changes and position their pipelines for future success.
Why It's Important?
The shift away from traditional animal testing in oncology research marks a significant transformation in the industry. This change is driven by the need for more accurate and predictive models that can better simulate human responses to treatments. The adoption of advanced technologies like CRISPR and AI in developing these models could lead to more effective therapies and improved patient outcomes. As the industry evolves, companies that adapt to these new methodologies may gain a competitive edge, potentially leading to breakthroughs in cancer treatment and a more efficient drug development process.
